Kisspeptin-10

Think of the reproductive system as a building's main electrical breaker. Kisspeptin is the hand that flips that breaker on, and scientists have proven in proper hospital studies that it works. They even noticed the lights flicker in the brain's romance rooms when they do it. But those tests were done by electricians with calibrated equipment for a few minutes at a time, often using a longer-lasting version of the switch. The vial you'd buy online is an unlabelled copy from an unknown workshop, and holding the breaker down constantly can trip the system rather than power it up.

Kisspeptin-10 binds and activates KISS1R (GPR54) on hypothalamic GnRH neurons, stimulating pulsatile GnRH secretion, which drives pituitary LH and FSH release and thus gonadal sex-steroid production. KISS1R is also expressed in limbic brain regions, where kisspeptin appears to directly modulate sexual and emotional processing partly independent of its downstream hormone effects.

Research contexts. Not proven uses, and not recommendations.

Substantial mechanistic human research exists, mostly from a single UK academic programme (Imperial College London). Controlled studies show kisspeptin reliably stimulates LH/FSH, can trigger oocyte maturation in IVF, and on fMRI modulates limbic sexual brain regions. Small randomised crossover trials in hypoactive sexual desire disorder reported increased sexual brain activity and some behavioural and physiological arousal signals. Most data are acute, intravenous and conducted in tightly controlled clinical settings. Much of the IVF and HSDD work used the longer kisspeptin-54 rather than KP-10 itself, whose specific human dataset is smaller. There are no large efficacy trials proving durable real-world benefit for libido or any condition, no licensed product, and continuous administration can desensitise the receptor.

• !No licensed kisspeptin-10 medicine anywhere. Products sold to consumers are unlicensed research chemicals marketed 'not for human consumption' with no guarantee of identity, purity or sterility.
• !Real human trial data used pharmaceutical-grade peptide in monitored settings, often the kisspeptin-54 form rather than KP-10. This does not validate self-administered grey-market product.
• !Continuous or repeated dosing can cause KISS1R desensitisation (tachyphylaxis), potentially blunting rather than boosting the reproductive axis.
• !Manipulating the master switch of the reproductive axis has predictable downstream hormonal consequences that are unmonitored outside a clinic.
• !Marketing hype around the 'libido peptide' far outstrips the short, small, early-stage and largely mechanistic nature of the actual human arousal evidence.
• !Injectable peptide carries the usual risks of contamination, dosing error and adverse reactions when used without medical supervision.

Not a licensed medicine in the UK. The MHRA has approved no kisspeptin-10 product. It remains an investigational compound studied under clinical trial authorisations and is an unlicensed substance otherwise. It is typically sold online as a research chemical labelled 'not for human consumption', which sidesteps medicines law. Supplying or marketing it for human medicinal use without authorisation would breach the Human Medicines Regulations 2012. There is no routine route to obtain it as a prescribed treatment in the UK outside a clinical trial or specialist research setting.

• · Early-phase randomised crossover (academic)· Completed/published 2023

  Kisspeptin in men with hypoactive sexual desire disorder (Imperial College London programme)

  Showed enhanced sexual brain processing and penile-tumescence signals; mechanistic rather than registrational.

• · Early-phase randomised crossover (academic)· Completed/published 2022

  Kisspeptin in women with hypoactive sexual desire disorder (Imperial College London programme)

  Increased BOLD activity in sexual brain networks vs placebo.

1. 01
   Kisspeptin modulates sexual and emotional brain processing in humans — Comninos AN, Wall MB, Demetriou L, et al., Journal of Clinical Investigation (2017)

   Landmark double-blind, placebo-controlled fMRI study in healthy men showing kisspeptin enhances limbic responses to sexual and bonding stimuli.

2. 02
   Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men — Narayanaswamy S, Jayasena CN, Ng N, et al., Human Reproduction (2015)

   Head-to-head human pharmacology of KP-10 vs KP-54 vs GnRH on LH/FSH; KP-10 and KP-54 broadly similar, GnRH most potent.

3. 03
   Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial — Mills EG, Ertl N, Wall MB, et al., JAMA Network Open (2023)

   Randomised crossover trial in men with HSDD; enhanced sexual brain processing and penile tumescence vs placebo.

4. 04
   Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial — Thurston L, Hunjan T, Ertl N, et al., JAMA Network Open (2022)

   Randomised crossover trial in women with HSDD; increased activity in sexual brain networks vs placebo.